Published in
Wiley, British Journal of Dermatology, 5(189), p. 635-637, 2023
DOI: 10.1093/bjd/ljad242
Links
Tools
The impact of biologic therapy for moderate-to-severe psoriasis on the immune responses to SARS-CoV-2 infection and vaccination
Journal article published in 2023 by
Rebecca Favaro 
,
Alessandra Formai ,
Giulia Pavia,
Luigi Gargiulo ,
Jessica Avagliano ,
Mario Valenti ,
Paola Facheris ,
Beatrice Salsano ,
Roberta V. Latorre ,
Francesco Bellinato ,
Paolo Gisondi ,
Alessandra Narcisi ,
Antonio Costanzo
,
Alessandra Formai ,
Giulia Pavia,
Luigi Gargiulo ,
Jessica Avagliano ,
Mario Valenti ,
Paola Facheris ,
Beatrice Salsano ,
Roberta V. Latorre ,
Francesco Bellinato ,
Paolo Gisondi ,
Alessandra Narcisi ,
Antonio Costanzo
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 
Abstract
Biologic therapy for moderate-to-severe psoriasis with anti-IL-23 and anti-IL-17 does not reduce the humoral and T-cell-mediated immune responses after COVID infection or vaccination; on the contrary, anti-IL-23 treatment was associated with a higher level of specific IgG following vaccination. In contrast, conventional therapies and TNF-α blockade reduce the production of specific antibodies.